Albert Labs International Corp C.ABRT

Alternate Symbol(s): ALBLF

Albert Labs International Corp. is a Canada-based pharmaceutical drug development company. The Company is focused on active compounds in the treatment of mental health and providing rapid access to effective prescription medicines for people suffering from mental health disorders. The Company operates primarily in one business segment: research and development of drugs to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs. The Company also focuses on developing solutions through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). The Company's first drug target, KRN-101, is a potential solution for cancer-related anxiety. KRN-101 is derived from natural psilocybin mycelium. Through collaborations with research institutions, hospital centers and government agencies, the Company uses existing clinical infrastructure to deliver and improve patient access to its treatment.